Estate (law)

First Surgeries Using Stryker’s Infinity With Adaptis and Everlast Successfully Completed in Europe

Retrieved on: 
Dienstag, Mai 7, 2024
Surgery, Medical Devices, Health, Clinical Trials, Health Technology, Hospital, Safety, North Tyneside General Hospital, Estate (law), Surgeon, Research, Titanium, Patient, SYK, Multimedia, Vitamin E, Dentistry

Stryker (NYSE:SYK), a global leader in medical technologies, announced the successful completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology.

Key Points: 
  • Stryker (NYSE:SYK), a global leader in medical technologies, announced the successful completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology.
  • The initial procedures were completed by Mr. David N. Townshend FRCS (Orth), Consultant Trauma & Orthopaedic Surgeon at North Tyneside General Hospital, United Kingdom, and are the start of the UK Infinity with Adaptis and Everlast study .
  • View the full release here: https://www.businesswire.com/news/home/20240506564749/en/
    Stryker's Infinity with Adaptis and Everlast Total Ankle System, featuring Prophecy Surgical Planning, is designed to deliver efficient and accurate implementation.
  • (Photo: Business Wire)
    “We are delighted to have implanted the first patient using Stryker’s Infinity Total Ankle System with Adaptis and Everlast technology as part of the UK post-market clinical study,” said Mr. Townshend.

To Drive a Deeper Understanding of Cancer Disparities, American Cancer Society Launches Largest U.S. Population Study of Black Women

Retrieved on: 
Dienstag, Mai 7, 2024
Mortality, Cancer, Health equity, United, Lung cancer, Risk, Woman, Health, Survival, Estate (law), American Cancer Society, Research, Area studies, Obesity, Female, ACS, Science, Diagnosis, Meat, Social justice, Tobacco, Birth control

ATLANTA, May 7, 2024 /PRNewswire/ -- Today, the American Cancer Society (ACS) is proud to announce the launch of the VOICES of Black Women® study, the largest behavioral and environmental focused population study of cancer risk and outcomes in Black women in the United States.  Designed to better understand the multi-level drivers of cancer incidence, mortality and resilience within this demographic, the long-term study will gather valuable data from Black women between the ages of 25 and 55 from diverse backgrounds and income levels who have not been diagnosed with cancer. The organization aims to enroll over 100,000 Black women across 20 states and D.C. where, according the U.S. Census, more than 90 percent of Black women in the U.S. reside.

Key Points: 
  • The organization aims to enroll over 100,000 Black women across 20 states and D.C. where, according the U.S. Census , more than 90 percent of Black women in the U.S. reside.
  • "VOICES of Black Women® represents a crucial step towards achieving health equity in a population that is long overdue," said Patel, co-principal investigator of the study and senior vice president of population science at the American Cancer Society.
  • The American Cancer Society believes everyone should have a fair and just opportunity to prevent, find, treat and survive cancer.
  • For more information about the VOICES of Black Women® study and how to participate, please visit voices.cancer.org .

Virginia Cancer Specialists Continues to Increase Access to Care in New, Expanded Fair Oaks, VA, Location, Now Open

Retrieved on: 
Donnerstag, Mai 2, 2024
Brain, Cancer, Genetics, Palliative care, Blood, Fairfax County Parkway, Suite, I-66, Elective surgery, Estate (law), Breast, Oncology, Research, FACS, Patient, Physician, Lung, Route, Social, Diagnosis, Radiation, Quality of life, Hematology, Genetic counseling, Breast cancer, Nursing

FAIRFAX, Va., May 2, 2024 /PRNewswire/ -- Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia, reinforces its commitment to providing exceptional cancer care and progressing clinical cancer research by expanding its third location in the last 6 months. Virginia Cancer Specialists serves patients in 10 locations throughout Northern Virginia with advanced, integrated, complete cancer care.

Key Points: 
  • Now in its 52nd year, Virginia Cancer Specialists continues to increase service and access to quality cancer care throughout Northern Virginia.
  • FAIRFAX, Va., May 2, 2024 /PRNewswire/ -- Virginia Cancer Specialists, the largest private cancer practice in Northern Virginia, reinforces its commitment to providing exceptional cancer care and progressing clinical cancer research by expanding its third location in the last 6 months.
  • Virginia Cancer Specialists serves patients in 10 locations throughout Northern Virginia with advanced, integrated, complete cancer care.
  • Founded in 1972, Virginia Cancer Specialists has been an integral part of the Northern Virginia medical community for over 50 years.

Rentec Direct Honored With Three Stevie® Awards In 2024 American Business Awards®

Retrieved on: 
Dienstag, April 30, 2024
Sale, Organization, Bronze, Estate (law), Customer service, High, Marriott Marquis, Gold, Stevie Awards, Silver, Growth, Film industry

GRANTS PASS, Ore., April 30, 2024 /PRNewswire-PRWeb/ -- Rentec Direct was named the winner of three Stevie® Awards in The 21st Annual American Business Awards®. The property management software company received a Gold Stevie® Award in the Entrepreneur of the Year category. The company also received a Silver Stevie® Award in the Customer Service Department of the Year category and a Bronze Stevie® award in the Real Estate Company of the Year. This is the seventh consecutive year that Rentec Direct has been recognized for its accomplishments in the American Business Awards® program.

Key Points: 
  • Property management software company, Rentec Direct, placed in national business awards for the seventh consecutive year, earning three Stevie® Awards from the 2024 American Business Awards.
  • GRANTS PASS, Ore., April 30, 2024 /PRNewswire-PRWeb/ -- Rentec Direct was named the winner of three Stevie® Awards in The 21st Annual American Business Awards®.
  • This is the seventh consecutive year that Rentec Direct has been recognized for its accomplishments in the American Business Awards® program.
  • Details about The American Business Awards and the list of 2024 Stevie winners are available at https://stevieawards.com/aba/2024-stevie-award-winners .

Aster Insights announces Johns Hopkins All Children's Hospital joins the Oncology Research Information Exchange Network (ORIEN)

Retrieved on: 
Dienstag, April 30, 2024
Patient, Cancer, Hospital, Health, Johns Hopkins, Estate (law), Collection, Research, History, TCC, Biomarker, Clinical trial, Knowledge, Pharmaceutical industry

TAMPA and ST. PETERSBURG, Fla., April 30, 2024 /PRNewswire/ -- Aster Insights, the leading provider of scientific and clinical intelligence for oncology discovery, announced today that Johns Hopkins All Children's Hospital will join its Oncology Research Information Exchange Network® (ORIEN) as the newest member of the consortium. By joining ORIEN®, children with cancer receiving care at Johns Hopkins All Children's Hospital will be able to participate in this research to identify novel oncology cures. With this addition, ORIEN® will be comprised of 19 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer medical product discovery and development.

Key Points: 
  • TAMPA and ST. PETERSBURG, Fla., April 30, 2024 /PRNewswire/ -- Aster Insights , the leading provider of scientific and clinical intelligence for oncology discovery, announced today that Johns Hopkins All Children's Hospital will join its Oncology Research Information Exchange Network® ( ORIEN ) as the newest member of the consortium.
  • By joining ORIEN®, children with cancer receiving care at Johns Hopkins All Children's Hospital will be able to participate in this research to identify novel oncology cures.
  • "The addition of Johns Hopkins All Children's Hospital to ORIEN is a major milestone in the history of ORIEN and Aster Insights," said Dr. Erin Siegel, ORIEN® Steering Committee Chair.
  • Aster Insights leads the Total Cancer Care study and oversees ongoing data and specimen collection from patients across ORIEN®.

SIGNET JEWELERS RAISES RECORD-BREAKING $8.75M BENEFITING ST. JUDE CHILDREN'S RESEARCH HOSPITAL®

Retrieved on: 
Dienstag, April 16, 2024
Sale, Cancer, Hope, ALSAC, Sterling, Signet Jewelers, Survival rate, Estate (law), Partnership, Research, Zale Corporation, Patient, Child, Jewellery

AKRON, Ohio, April 16, 2024 /PRNewswire/ -- Signet Jewelers, the world's largest retailer of diamond jewelry, which includes KAY Jewelers, Zales, Jared and Banter by Piercing Pagoda, announced today it has raised $8.75 million for St. Jude Children's Research Hospital® in connection with its previously announced commitment to raise $100 million.

Key Points: 
  • This record-breaking contribution is Signet's largest one-time donation to St. Jude yet and represents the highest amount Signet has ever raised in one year for St. Jude.
  • Signet's over 26,000 North American team members proudly support the work with St. Jude.
  • The St. Jude LIFE Study program is an unprecedented research study aimed at increasing survivorship and also helping cancer survivors to thrive.
  • In October, Signet celebrated raising more than $100 million throughout its 25-year partnership with St. Jude and committed to raising another $100 million.

International open competition launched to find a design team for the new museum of architecture and design in Helsinki, Finland

Retrieved on: 
Montag, April 15, 2024
GFA, Real estate, City, Esplanade Park, Jane, Estate (law), Heart, Urban renewal, Marimekko, Aino, Employment, History, A3, Public policy, Culture, Museum, Society, Jury, World Design Capital, ADM, Fiskars, UNESCO, SAFA, Nokia, Stage 2, Name, Running

An international open design competition is launched to find a design team for a new museum building on a site in Helsinki's South Harbour.

Key Points: 
  • An international open design competition is launched to find a design team for a new museum building on a site in Helsinki's South Harbour.
  • The building will provide a home for the new museum of architecture and design formed through the merger of the Design Museum Helsinki and the Museum of Finnish Architecture.
  • The new museum of architecture and design in Helsinki, Finland, is planned to open in 2030 and will combine the Museum of Finnish Architecture and Design Museum Helsinki.
  • We're delighted to launch this international open competition to find an architect for the new museum of architecture and design.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Donnerstag, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Biotech Innovations Paving the Way in Breast Cancer Fight

Retrieved on: 
Donnerstag, April 11, 2024
AstraZeneca, Breast cancer, Gilead Sciences, FDA, Radiation, University, PARP1, Cancer, Bone marrow, G1 Therapeutics, Paclitaxel, Protein, GILD, Safety, PARP, Pancreatic cancer, News, Progression-free survival, Survival, Estate (law), American Cancer Society, TSX, OS, Fast track (FDA), MBC, ONC, PETRA, Data monitoring committee, Rated R, Patient, Sacituzumab govitecan, Hologic, HOLX, Neoplasm, Death, DMC, AACR, Immune system, Type, TNBC, Trilaciclib, Pharmaceutical industry

VANCOUVER, BC, April 11, 2024 /PRNewswire/ -- USA News Group – The American Cancer Society is projecting 2024 to be the first year ever for the US to have more than 2 million new cases, which would represent a record high. Among 10 of the most common cancers, 6 have seen a rise in diagnoses, including the most common type of cancer in women—breast cancer. According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022, and is predicting a 77% increase in new cancer cases by 2050. Based on the characteristics of each patient's tumor, how each patient is treated may be completely different from others. Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).

Key Points: 
  • According to the World Health Organization breast cancer caused 670,000 deaths globally in 2022 , and is predicting a 77% increase in new cancer cases by 2050 .
  • Broadening our ability to tackle breast cancer are several biotech developments including from Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Gilead Sciences, Inc. (NASDAQ:GILD), G1 Therapeutics, Inc. (NASDAQ:GTHX), AstraZeneca PLC (NASDAQ:AZN), and Hologic, Inc. (NASDAQ:HOLX).
  • Coming off of a late-2022 FDA Fast Track Designation of Oncolytics Biotech Inc.'s (NASDAQ:ONCY) (TSX:ONC) flagship asset pelareorep for the treatment of pancreatic cancer, momentum is building towards another important FDA milestone, this time for breast cancer.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.

Mutual funds and safe government bonds: do returns matter?

Retrieved on: 
Donnerstag, April 25, 2024
ACT, Safe Haven, Research Papers in Economics, Flight, Policy, B.3, ICAPM, RT, Journal of International Economics, Krishnamurti, Business, CIP, International, Observation, P25, Safety, A23, Benchmarking, B.2, FX, Paper, TSD, Environment, Journal of Financial Economics, Bogdanov, Federal, Website, United, A14, Total, The Economic Journal, Eurozone, Face, G11, Quarterly Journal of Economics, Interest rate parity, History, WD, Investment, Liquidity premium, Politics, OLS, Statistics, G15, Caballero, PDF, Classification, ECB, Foreign exchange market, AC, P99, Federal funds, Froot, Lethargy, Social science, Interest, JEL, Bias, Journal, Research, Journal of Economic Literature, The Journal of Finance, E.3, Literature, Federal Reserve, Parity, European Central Bank, AA, Annual Review, Growth, Bank of England, FRED, S&P, Injection, Risk, Elasticity, Government, G12, Finance, BIS, S1, JL, E.1, Money, Depreciation, Asset, Treasury, Federal Reserve Economic Data, A11, A10, R2, Section 4, UMP, A4, Boj, Section 3, Accounting, SJ, Fed, Mutual fund, Lustig, University of Lausanne, Section 2, P75, Foreign-exchange reserves of India, Assets under management, A19, GBP, FE, American Economic Review, A22, E.5, A3, A21, Flight-to-liquidity, Aggregate demand, G23, WT, USD, Autocorrelation, CAD, UIP, Currency, XR, Quarterly Journal, Appendix H, Capital, P95, A6, Zhu, University, B.1, P50, CHF, Transmission, Swings, Estate (law), EUR, Bank for International Settlements, JPY, E.4, Central bank, Multicollinearity, Bank, Fixed effects model, Reproduction, CAP, The Atlanta Jewish Times, VIX, Data, Om, Lobster
Key Points: